thought call
alexion third beat/rais broadli good result
sell news tape today share pressur nbi index
sentiment still seem fragil mostli concern competit landscap
sever compani present updat data meet dec san
diego come surpris one competit complement
front noisi sever year view competit concern
complet overshadow remark transform alexion
past month includ return top tier growth revenu
non-gaap ep new product cycl soliri launch nmo
gmg ou ultomiri launch pnh expand
mid late-stag pipelin deal year wilson syntimmun dicerna
lower risk profil major headlin pricing/reimbursement/
access get competit concern ip worri alexion strateg
play offens defens effect wed argu compani
well-posit strong given necessari invest
model non-gaap ep growth impress revenu growth
acceler given strong fundament attract
risk/reward profil alexion remain top pick maintain ow rate pt
pipelin updat sc formul phase remain track start
gmg trial set earli phase anoth sc formul
initi beyond complement phase remain on-going
potenti file track data phase waiha like
compani intend start pivot phase afterward data ultomiri
ahu expect event watch includ eu patent decis
pdufa date ultomiri pnh follow prioriti review
model chang follow call modestli increas
revenu forecast respect
also updat opex outlook result non-gaap ep
estim increas respect vs prior
quarterli annual ep usd
barclay research consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
growth soliri pnh/ahu growth driven
sale refractori gmg assum
approv extend dose option
pnh ahu support long-term
viabil complement franchis recent fx
improv
greater expect growth soliri current
indic ahu pnh gmg label
expans soliri nmo posit data
rapid uptak iv
subcutan formul support upsid case
biosimilar competit soliri
time frame high price pressur ww
geographi addit failur
pnh ahu increas fx headwind
macroeconom issu support downsid case
except per op analysisnewnewnewnewr barclay
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
